Next Article in Journal
Schmallenberg Disease—A Newly Emerged Culicoides-Borne Viral Disease of Ruminants
Next Article in Special Issue
Towards Understanding KSHV Fusion and Entry
Previous Article in Journal
Molecular Dynamics Simulation Reveals Exposed Residues in the Ligand-Binding Domain of the Low-Density Lipoprotein Receptor that Interacts with Vesicular Stomatitis Virus-G Envelope
Previous Article in Special Issue
Identification of Novel Natural Products as Effective and Broad-Spectrum Anti-Zika Virus Inhibitors
Open AccessArticle

Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator

Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences and Shanghai Public Health Clinical Center, Shanghai Medical College, Fudan University, Shanghai 200032, China
*
Authors to whom correspondence should be addressed.
Viruses 2019, 11(11), 1064; https://doi.org/10.3390/v11111064
Received: 12 October 2019 / Revised: 30 October 2019 / Accepted: 10 November 2019 / Published: 15 November 2019
(This article belongs to the Special Issue Viral Entry Pathways)
Recently, Zika virus (ZIKV) has attracted much attention in consideration of its association with severe neurological complications including fetal microcephaly. However, there are currently no prophylactic vaccines or therapeutic drugs approved for clinical treatments of ZIKV infection. To determine the potential anti-ZIKV inhibitors, we screened a library of clinical drugs with good safety profiles. Erythromycin estolate (Ery-Est), one of the macrolide antibiotics, was found to effectively inhibit ZIKV infection in different cell types and significantly protect A129 mice from ZIKV-associated neurological signs and mortality. Through further investigation, Ery-Est was verified to inhibit ZIKV entry by disrupting the integrity of the viral membrane which resulted in the loss of ZIKV infectivity. Furthermore, Ery-Est also showed inhibitory activity against dengue virus (DENV) and yellow fever virus (YFV). Thus, Ery-Est may be a promising drug for patients with ZIKV infection, particularly pregnant women. View Full-Text
Keywords: erythromycin estolate; ZIKV; viral entry inhibitor; inactivator erythromycin estolate; ZIKV; viral entry inhibitor; inactivator
Show Figures

Figure 1

MDPI and ACS Style

Wang, X.; Xia, S.; Zou, P.; Lu, L. Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator. Viruses 2019, 11, 1064.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop